Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?

Pelvic Melanoma relapse occurs in 15% of patients with loco regional metastases, and 25% of cases do not respond to new target-therapy and/or immunotherapy. Melphalan hypoxic pelvic perfusion may, therefore, be an option for these non-responsive patients. Overall median survival time (MST), stratifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guadagni, Stefano, Fiorentini, Giammaria, Clementi, Marco, Palumbo, Giancarlo, Palumbo, Paola, Chiominto, Alessandro, Baldoni, Stefano, Masedu, Francesco, Valenti, Marco, Di Tommaso, Ambra, Fabi, Bianca, Aliberti, Camillo, Sarti, Donatella, Guadagni, Veronica, Pellegrini, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713351/
https://www.ncbi.nlm.nih.gov/pubmed/29120401
http://dx.doi.org/10.3390/ijms18112382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713351/
https://www.ncbi.nlm.nih.gov/pubmed/29120401
http://dx.doi.org/10.3390/ijms18112382

Ejemplares similares